Vioxx Label Balances CV Risk With GI Safety: Can Merck Reverse Damage?

The Vioxx labeling change will allow Merck to discuss the COX-2 inhibitor's cardiovascular safety profile in the context of a rheumatoid arthritis indication and a gastrointestinal safety benefit